ESTRO 2023 - Abstract Book

S488

Sunday 14 May 2023

ESTRO 2023

Conclusion Moderately hypo-fractionated RT 44Gy/20F with concurrent cisplatin showed no significant difference in acute toxicity and tumor response comparing to 45Gy/25F in this interim analysis. Significantly reduced OTT were achieved, moreover maintain ability to reduce GTV before brachytherapy. Longterm result after completion of HYPOCx-iRex is awaited to elucidate the non-inferiority of hypofractionated RT in locally advanced cervical cancer. OC-0605 Patient-reported peripheral neuropathy in cervix cancer patients: a trajectory analysis A.T. Frederiksen 1 , M. Pelizzola 2 , K. Kirchheiner 3 , I.M. Jürgenliemk-Schulz 4 , R.A. Nout 5 , M.P. Schmid 3 , K. Tanderup 2 , L.T. Tan 6 , S. Spampinato 1 1 Aarhus University Hospital, Danish Center for Particle Therapy , Aarhus, Denmark; 2 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark; 3 Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria; 4 University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands; 5 Erasmus MC, Department of Radiation Oncology , Rotterdam, The Netherlands; 6 Cambridge University Hospitals NHS Foundation Trust, Oncology Centre, Cambridge, United Kingdom Purpose or Objective Peripheral neuropathy (PN) is a common side-effect after chemoradiation. Previous studies found that persistent patient- reported PN has major impact on long-term quality of life (QoL) among patients treated for locally advanced cervical cancer (LACC). Materials and Methods The analysis was conducted within the prospective, multi-institutional and international EMBRACE-II study which enrolled LACC patients (2016-2021) treated with external beam radiotherapy, concomitant weekly cisplatin, and image-guided adaptive brachytherapy. Symptoms of PN were prospectively scored with the EORTC CX24 questionnaire by patients at baseline and regular follow- ups. The question analyzed was “Have you had tingling or numbness in your hands or feet?” and score options were: “not at all”, “a little”, “quite a bit” and “very much”. This longitudinal analysis included patients reporting these symptoms at least at baseline and at 3 late follow-ups (FUPs). Late follow up was defined as at 3 months after end of treatment and up till 24 months. Late persistency (LAPERS) of PN was calculated based on the median score of PN across all late FUPs (3 months to 24 months). Late persistency of PN was defined if patients scored “a little or worse” and “quite a bit or worse” in at least of half of FUPs, respectively (Figure1). Trajectory analysis (TJA) was used to group patients based on their longitudinal time patterns of PN development over the observation period and identify relevant clusters. This analysis evaluates persistency and identifies time development patterns of patient-reported PN among LACC patients.